Neurophysiological mechanisms of cognitive impairment in Severe Myoclonic Epileps

婴儿期严重肌阵挛癫痫(SMEI)，又称Drave氏综合征，是一种与Scn1a功能丧失突变有关的儿童障碍，其特征是频繁癫痫发作和严重认知障碍。患者往往对抗癫痫药物难以治愈，在以后的生活中无法恢复正常的认知功能。为了确定适当的治疗策略以改善认知结果，首先有必要了解认知功能障碍的潜在生物学贡献。虽然癫痫的认知缺陷通常被归因于癫痫发作的影响，但我们认为与SMEI相关的遗传缺陷会导致大脑网络活动的神经生理学改变，并导致独立于癫痫发作的认知障碍。这种可能性可能对研究未来旨在改善认知的治疗方法具有重要意义。这表明，仅靠治疗癫痫发作可能无法完全恢复认知功能。因此，这项研究对于确定是否应该在传统抗癫痫药物的基础上寻求额外的治疗策略，以努力开发改善认知结果的治疗方法将是重要的。 Scn1a基因编码I型电压门控钠通道。在前脑，Scn1a缺陷会导致小白蛋白阳性中间神经元(PV)动作电位放电受损，但不会导致兴奋性锥体细胞。除了这种类型的细胞在大脑中平衡兴奋和抑制之外，PV中间神经元在神经网络的时空模式中发挥着关键作用，特别是在认知过程中。在隔区-海马体系统中，这些细胞是脑网络振荡和时间编码所必需的，而这种中间神经元群体中的选择性损伤会导致学习和记忆任务中的认知表现受损。因此，隔-海马区系统可能是一个受Scn1a缺陷影响的网络。这项提案的目标是解决Scn1a缺陷是否会导致认知障碍的问题。我们假设，隔区-海马区系统中的Scn1a缺陷足以损害独立于癫痫障碍的认知。我们将使用体内电生理和行为技术，结合RNAi沉默大鼠Scn1a的表达来验证这一假说。我们的具体目标是(1)确定隔区-海马系统中Scn1a缺陷对认知的影响，以及(2)研究Scn1a缺陷对神经网络振荡和编码的影响。这些实验对于阐明可能导致Scn1a基因突变导致认知障碍的神经网络机制将是重要的。

Severe Myoclonic Epilepsy in Infancy (SMEI), also referred to as Dravet syndrome, is a childhood disorder associated with loss-of-function mutations in Scn1a that is characterized by frequent seizures and severe cognitive impairment. Patients are often intractable to anti-epileptic drugs and do not recover normal cognitive function later in life. In order to determine appropriate treatment strategies for improving cognitive outcomes, it is first necessary to understand the underlying biological contributions to cognitive dysfunction. Although the cognitive deficits in epilepsy are often attributed to the impact of seizures, we propose that the genetic deficit associated with SMEI leads to neurophysiological alterations in brain network activity and contributes to cognitive impairment independently of seizures. This possibility may hold important implications for investigating future treatments aimed to improve cognition. It would suggest that cognitive function may not fully recover by treating seizures alone. This investigation will therefore be important to determine if additional treatment strategies to the traditional anti-epileptic drugs should be pursued in the effort to develop therapies for improving cognitive outcome. The Scn1a gene encodes for the type I voltage-gated sodium channel. In the forebrain, Scn1a deficits cause impaired action potential firing of parvalbumin-positive (PV+) interneurons but not excitatory pyramidal cells. In addition to the contribution of this cell type to balancing excitation and inhibition in the brain, PV+ interneurons play critical roles in the spatiotemporal patterning of neural networks, especially during cognitive processes. In the septo-hippocampal system, these cells are required for brain network oscillations and temporal coding, and selective impairments in this interneuron population result in impaired cognitive performance on learning and memory tasks. Therefore, the septo-hippocampal system may be one network affected by Scn1a deficits. The goal of this proposal is to address the question of whether Scn1a deficits contribute to cognitive impairment. We hypothesize that Scn1a deficits in the septo-hippocampal system are sufficient to impair cognition independently of the seizure disorder. We will use in vivo electrophysiological and behavioral techniques combined with RNAi silencing of Scn1a expression in rats to test this hypothesis. Our specific aims are to (1) determine the effects of Scn1a deficits in the septo-hippocampal system on cognition, and (2) to investigate the effects of Scn1a deficits on neural network oscillations and coding. These experiments will be important for elucidating a neural network mechanism that may contribute to impaired cognition caused by Scn1a gene mutations.